Clinical trials
Advanced Gastric Cancer clinical trials
Below are recruiting advanced gastric cancer clinical trials, each written for real people, not researchers. We’re tracking 410 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06529718RecruitingPhase 2
Ivonescimab vs FOLFOX for advanced bile duct cancer
This trial tests a new drug, ivonescimab, compared to standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has progressed after initial treatment. It aims to see if ivonescimab can help control the cancer better.
AmiensAges 18 years+ - NCT04802759RecruitingPhase 1/Phase 2
Testing drug combinations for recurrent or advanced ER-positive breast cancer
This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.
Duarte, CaliforniaAges 18 years+ - NCT04150640RecruitingPhase 2
Chemo drug combination for advanced stomach or esophagus cancer
This Phase 2 trial tests whether a combination of chemo drugs (oxaliplatin and liposomal irinotecan) plus trastuzumab works better for people with advanced stomach or esophagus adenocarcinoma that has specific tumor markers (HER2 and PDL1). It may help shrink tumors and improve control of the cancer in people who have not had prior treatment for advanced disease.
Madison, WisconsinAges 18 years+ - NCT05427383RecruitingPhase 2/Phase 3
KN026 plus chemo for HER2-positive stomach cancer after first treatment failure
This trial tests KN026 together with chemotherapy in people with HER2-positive advanced stomach (or gastro-esophageal junction) cancer that has already grown despite first-line treatment with trastuzumab plus chemotherapy. It may help by targeting HER2 while also using chemotherapy to control the cancer.
BeijingAges 18 years+ - NCT07829081Recruiting
Watch-and-wait after immunotherapy for early-stage GI cancers
This study looks at whether some patients with early-stage stomach, colon, or rectal cancers that are mismatch repair-deficient (a genetic feature making them more likely to respond to immunotherapy) can safely avoid surgery and instead be monitored closely after treatment with immunotherapy. It aims to confirm if this watch-and-wait approach is as effective and helps patients avoid major operations.
BaselAges 18 years+ - NCT06821048RecruitingPhase 1
CAR-T cells targeting CEA for advanced solid tumors
This trial tests a new treatment called CAR-T cells that are designed to attack cancer cells positive for CEA protein. It's for people with advanced solid tumors like colorectal or lung cancer who have run out of standard options.
Hangzhou, ZhejiangAges 18 years+ - NCT05969171RecruitingPhase 2
Surufatinib plus chemotherapy for advanced pancreatic cancer
This Phase 2 study tests whether adding surufatinib to first-line treatment (either AG or a similar AG-based regimen) can improve outcomes for people with locally advanced or metastatic pancreatic cancer. You may be considered if your cancer cannot be removed by surgery and you’ve already had a short course of similar treatment with a response.
ShanghaiAges 18–75 - NCT06562543RecruitingPhase 4
Fruquintinib for advanced colorectal cancer in minority populations
This trial tests a medication called fruquintinib (an oral pill) for people with advanced colorectal cancer that has not responded to prior treatments. It is specifically looking for participants who identify as Black or African American and/or Hispanic or Latino to help understand how the drug works in these groups.
Birmingham, AlabamaAges 18 years+ - NCT07799935Recruiting
Tumor ablation after chemo for advanced pancreatic cancer
This study tests a procedure called irreversible electroporation (IRE), which uses electric pulses to destroy cancer cells, after chemotherapy for advanced pancreatic cancer that hasn't spread. It aims to control the tumor and improve outcomes in people who are not eligible for surgery.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06124963RecruitingPhase 2
WX390 plus Toripalimab for STK11-mutated cervical cancer
This trial tests a combination of an experimental pill (WX390) and an immunotherapy drug (Toripalimab) for a specific type of cervical cancer that has an STK11 gene change. It aims to see if this combination can shrink tumors or slow the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06371586RecruitingPhase 2
Neo-Sequence 2: New drug combo for advanced stomach cancer
This trial tests a new treatment plan for advanced stomach cancer using chemotherapy, anti-angiogenesis therapy (to cut off tumor blood supply), and immunotherapy (to help your immune system fight cancer). The goal is to see if this combination works better before surgery.
BeijingAges 18–75 - NCT05319639RecruitingPhase 1/Phase 2
Irinotecan plus immunotherapy for stomach cancer
This Phase I/II trial tests how well irinotecan combined with tislelizumab (an immunotherapy) treats advanced stomach or gastroesophageal junction adenocarcinoma. It mainly looks at safety and the best way to use this combination, and may help shrink tumors or slow disease growth.
Fuzhou, FujianAges 18–75 - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Denver, ColoradoAges 18 years+ - NCT05563012RecruitingPhase 2
Short radiation plus chemo and PD-1 immunotherapy for stomach cancer
This Phase 2 trial tests whether giving a short course of radiation before surgery, along with chemotherapy and a PD-1 immunotherapy drug, can improve treatment outcomes for locally advanced stomach cancer. It may help shrink the tumor before surgery and strengthen the immune system’s attack on cancer.
Wuhan, HubeiAges 18–75 - NCT05813015RecruitingPhase 3
Testing S-1 after stomach cancer surgery with or without sequence therapy
This Phase 3 study compares two ways of giving S-1 medicine after curative stomach cancer surgery in stage III disease. It aims to see whether the sequential approach improves outcomes while keeping treatment safe.
Hanzhou, ZhejiangAges 18–75 - NCT05640609RecruitingPhase 1/Phase 2
Stomach cancer study using chemo plus immunotherapy plus targeted drug
This Phase 1/2 trial tests a combination treatment for advanced or metastatic stomach and food-pipe (gastroesophageal junction) cancer: a chemotherapy regimen (CapeOX) plus the immunotherapy drug sintilimab and the targeted drug bevacizumab. It aims to see how well this combination controls the cancer and how safely it can be given.
ChengduAges 18–70 - NCT05729646RecruitingPhase 2
Pre-surgery chemotherapy with toripalimab for dMMR stomach cancer
This trial studies whether adding toripalimab (an immune therapy) to chemotherapy before and around surgery can improve outcomes for people with certain mismatch repair–deficient stomach cancers. It mainly targets tumors that are dMMR and not HER2-positive.
Hangzhou, ZhejiangAges 18–80 - NCT05872685RecruitingPhase 2
Perioperative chemo plus serplulimab for specific stomach cancers
This Phase 2 trial tests whether adding serplulimab (an immune medicine) to standard chemotherapy before and/or around surgery can improve outcomes for people with certain locally advanced stomach cancer. You may get serplulimab or a placebo, and researchers will compare results to see if the immune add-on helps.
Hangzhou, ZhejiangAges 18–80 - NCT05918094RecruitingPhase 3
Testing new chemo plan plus immunotherapy for stomach cancer
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07646574Enrolling by invitation
Non-surgical treatment after immunotherapy for specific gastric cancer
This trial tests whether patients with advanced gastric cancer (a specific type called dMMR/MSI-H) can be treated without surgery after receiving immunotherapy and chemotherapy. The goal is to see if this approach can control the cancer while avoiding the risks of surgery.
Chengdu, SichuanAges 18 years+ - NCT07353684RecruitingPhase 2
Adebrelimab plus apatinib with chemo for gastric cancer
This trial tests a combination of two targeted drugs (adebrelimab and apatinib) with standard chemotherapy (SOX regimen) before surgery for gastric cancer that cannot be removed right away. The goal is to shrink the tumor enough to make surgery possible.
Beijing, Beijing MunicipalityAges 18–75 - NCT07253948Recruiting
H. pylori bacteria location in the stomach
This study looks at where H. pylori bacteria are found in the stomach. If you have tested positive for H. pylori through a stomach biopsy and haven't had stomach surgery or serious health issues, you may be able to join.
Changchun, JilinAges 18–80 - NCT07094685RecruitingPhase 2
Ivonescimab before surgery for head and neck cancer
This study tests a new immunotherapy drug called ivonescimab given before surgery for people with advanced head and neck cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
Ann Arbor, MichiganAges 18 years+ - NCT05180864Recruiting
Omentum saving surgery versus full removal in stomach cancer
This study compares two ways of doing surgery for gastric (stomach) cancer: saving the omentum versus removing it completely. It may help doctors learn which approach is safer and works better for cancer control and recovery.
MainzAges 18 years+
Hear when a new Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced gastric cancer?
- Yes. Clin2 currently lists 410 recruiting advanced gastric cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced gastric cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced gastric cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.